Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Medicinal Chemistry.Register Now
KEY OPINION LEADERS
The Medicinal Chemistry Roundtable Discussions Strategy Meeting is free to attend for qualified end-users.These include Senior Executives of Early Drug Discovery (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Chemistry, Immunology Chemistry, Chemistry Technologies, Medicinal and Innovative Chemistry, Drug Discovery & DMPK, Chemical and Molecular Therapeutics, Chemical Development, Biochemistry & Molecular Pharmacology, Computational and Structural Chemistry, Biochemistry.
Those who do not qualify for complimentary passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Senior Vice President, Research, Intercept Pharmaceuticals
Vice President, Discovery Chemistry, Genentech
Medicinal Chemistry Division.
Vice President, Global Medical and Diagnostic Affairs, Ignyta, Inc.
Steve served as the Founding CEO of Flagship Biosciences. He led the company from inception to over 80 employees and collaborations with 100 pharmaceutical companies in tumor immunology, rare disease, and targeted therapy drug development.
He was also Scientific Director and then Vice President of Life Sciences for Aperio (acquired by Danaher).
He built the first Clinical Bioinformatics Department at Quest Diagnostics Nichols Institute, supporting the world’s largest clinical molecular genetics testing laboratory, and one of the first to provide clinical whole gene sequencing.
He is the editor of the book “Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development” and is author on over 40 peer-reviewed publications and patents.
He holds a Ph.D. in Biological Engineering, an MS in Bioengineering and an MBA, all earned at the University of California at Davis. His Bachelor’s training is in Physics from Wheaton College, Illinois.
Vice President, Drug Discovery, FLX Bio
David received his B.S. degree from the Pennsylvania State University and holds a Ph.D. in Organic Synthesis from The University of Rochester. He is the author of over 40 peer previewed publications and an inventor on over 30 US patents.
Vice President, Cellerant Therapeutics
Vice President, Drug Discovery, Principia Biopharma
Executive Director Head of Chemistry, Merck
Senior Vice President, Discovery Technologies
Klaus Urbahns has more than 20 years of experience in the biopharmaceutical industry. He is Senior Vice President, Head of the Discovery Technology Platform at MerckSerono with laboratories in the US, Israel and Germany. His team’s role is to generate small molecule drug candidates and therapeutic proteins. Prior to joining Merck, Klaus served at AstraZeneca in the UK and Sweden. He started his professional career at Bayer, holding positions in Germany and Japan. Klaus is member of the advisory board of the Lead Discovery Center (LDC) and the Medicines for Malaria Venture (MMV). Klaus studied chemistry at the universities of Kiel, Freiburg and Frankfurt.
Vice President, Discovery Research Site Head, Austria
Darryl McConnell is currently Research Site Head and Head of Medicinal Chemistry at Boehringer-Ingelheim Regional Centre Vienna, Austria where the main research focus is oncology. Darryl commenced his career with Boehringer-Ingelheim in 2002 as a Research Laboratory Head and is in his current role since 2015.
Prior to this Darryl has worked for Intervet in Vienna from 2001, for Biota Holdings Ltd in Melbourne, Australia from 1999 in the area of respiratory viruses and Chiron Technologies in Melbourne from 1997.
Darryl McConnell received his Bachelor of Science with First Class Honours in 1991 with Professor John Elix at the Australian National University in Canberra. He performed his PhD at the University of New South Wales in Sydney with Professor David Black for which he was awarded the Cornforth Medal for the best chemistry PhD thesis in Australia for that year. Following this he performed a 2 year Postdoctoral study at the University of Sydney with Professor Leslie Field in organometallic chemistry.
Darryl’s interest lie in the areas of cancer cell directed and immune cell directed therapies for cancer as well as protein crystallography and protein NMR, fragment based and structure based drug discovery, drug discovery software development, agile methods in drug discovery and natural product inspired medicinal chemistry.
Senior Vice President, Chemistry
Jean Kim is a Senior V.P. of Chemistry at Kadmon where she currently leads the discovery of small molecule therapeutic agents for Oncology, Autoimmunity, and Anti-infective diseases. She directed numerous research programs at Merck and Wyeth Laboratories and has worked in the field of Medicinal Chemistry Research for over 20-years, towards finding therapies for Metabolic Syndrome and Diabetes, and Neurological disorders. Jean is a co-inventor of Nemonoxacin, an antibiotic marketed for the treatment of community-acquired pneumonia (CAP). Jean received her Ph.D. in organic chemistry from University of Illinois, at Champaign-Urbana, and completed post-doctoral research in University of Basel, Switzerland after receiving her B.S. in chemistry from Cornell University.
Medicinal Chemistry Strategy Meeting US East Coast 2016,
Hyatt Regency Airport Hotel, San Francisco
1333 Bayshore Highway, Burlingame, California